A study to look at how safe different doses of the study medicine - DCDS0780A - were for patients with non-Hodgkin’s Lymphoma that involved B cells
A Study of Escalating Doses of DCDS0780A in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Cancer Non Hodgkin Lymphoma (NHL)
Basic Details
DCDS0780A is a new medicine known as an antibody-drug conjugate or “ADC”. Patients with non-Hodgkin’s Lymphoma that involved B cells received different doses of DCDS0780A to help researchers find out which dose was safe. In a second part to this study, patients got DCDS0780A with an approved medicine called “rituximab”. Researchers wanted to know if DCDS0780A was safe when used with rituximab.
This page summarises information from public registry websites, such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. To learn more about this study, see the For Medical Professional tab or visit one of those websites.
The information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.
Results Disclaimer
For the latest version of this information please go to www.forpatients.roche.com